Literature DB >> 3135321

Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody.

S Banerjee1, B Y Wei, K Hillman, H S Luthra, C S David.   

Abstract

The use of an anti-IL-2R antibody, 7D4, was investigated in vivo in the suppression of collagen-induced arthritis in mice. 7D4 was shown to reduce the incidence of arthritis in a group of mice immunized with type II collagen as compared with a group similarly immunized with collagen and treated with a control isotype matched anti-Forsmann antibody. 7D4 was also shown to reduce the severity of arthritis in the treated mice as compared to the mice in the group treated with the control antibody. Anti-IL-2R antibodies may be useful in the treatment of autoimmune diseases by selectively suppressing activated T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135321

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Immunotherapy of rheumatoid arthritis.

Authors:  R A Watts; J D Isaacs
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

Review 4.  Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

Authors:  R O Williams
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody.

Authors:  I Wiesenberg; P H Van der Meide; H Schellekens; S Alkan
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

6.  Monoclonal antibodies and arthritis.

Authors:  M E Billingham; C Hicks; S Carney
Journal:  Agents Actions       Date:  1990-01

7.  Evaluation of carboxymethylpullulan as a novel carrier for targeting immune tissues.

Authors:  K Masuda; M Sakagami; K Horie; H Nogusa; H Hamana; K Hirano
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

Review 8.  The genetic and immunopathological processes underlying collagen-induced arthritis.

Authors:  J A Luross; N A Williams
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

9.  TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis.

Authors:  P Mukherjee; B Wu; L Mayton; S-H Kim; P D Robbins; P H Wooley
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

10.  Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.

Authors:  Juergen L Foell; Belkis I Diez-Mendiondo; Oliver H Diez; Ursula Holzer; Peter Ruck; Abhijit S Bapat; Michael K Hoffmann; Robert S Mittler; Guenther E Dannecker
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.